November 8, 2013: U.S. markets opened slightly higher Friday morning after the monthly report on non-farm payrolls showed a larger-than-expected gain. The preliminary report on November consumer sentiment came in low�pushing share prices down shortly after markets opened. It appears that investors decided to buy the dip today, though, retracing much of yesterday�� loss. The dollar strengthened again today, and the 10-year Treasury yield zoomed higher.
European markets closed mixed today while Latin American and Asian markets again closed lower.
Monday�� calendar includes speeches by Fed Governor Jerome Powell and Boston Fed President Eric Rosengren and the following scheduled data releases and events (all times Eastern):
10:00 a.m. – Factory orders 11:30 a.m. – 3- and 6-month bill auctionsHere are the closing bell levels for Friday:
S&P500 1770.60 (+23.45; +1.34%) DJIA 15761.78 (+167.80; +1.08%) NASDAQ 3919.23 (+61.90; +1.60%) 10YR TNOTE 2.751% (-1.21875) Gold $1,284.60 (-23.90; -1.8%) and down 2.2% for the week WTI Crude oil $94.60 (+0.40; +0.4%) and unchanged for the week Euro/Dollar: 1.3364 (-0.0055; -0.41%)Big Earnings Movers: The Walt Disney Co. (NYSE: DIS) is up 2.1% at $68.58 on a good showing for its films but not so much for its TV programming. Molycorp Inc. (NYSE: MCP) is up 1.8% at $4.85 after offering a weakish outlook. Revolution Lighting Technologies Inc. (NASDAQ: RVLT) is up 21.5% at $3.28 after a strong report and reaffirmed solid outlook.
Top 5 Net Payout Yield Stocks To Buy Right Now: Neuroderm Ltd (NDRM)
Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.
ND0612L for moderate Parkinson�� disease
ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.
The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.
The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.
ND0612H for severe Parkinson�� disease
The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.
ND0680 for severe Parkinson�� disease
ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680
ND0701 for severe Parkinson�� disease
ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.
ND0801 for Cognitive Disorders
ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.
The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.
Advisors' Opinion:- [By Johanna Bennett]
NeuroDerm (NDRM) almost tripled in value to $18.14 during regular market hours after posting clinical trial results for its experimental treatment for Parkinson�� disease.
- [By Johanna Bennett]
NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.
Hot Tech Companies To Buy For 2014: Silicon Graphics International Corp(SGI)
Silicon Graphics International Corp. provides computing and storage, and data center solutions, as well as related customer support and professional services. The company offers scale up servers; scale out servers; work group servers; data storage systems; and software products for technical computing, as well as data center infrastructure products, including ICE Cube Air, a modular data center that augments or replaces traditional brick-and-mortar data centers; and MobiRack, a line of mobile, all-in-one data center cabinets for field deployments. Its products and services are used by the scientific, technical, and business communities for solving challenging data-intensive computing, data storage, and management problems. The company also develops system applications, such as simulating global climate changes, accelerating engineering of new automotive designs, supporting homeland security initiatives, real-time fraud detection, streaming media from Internet-video to film , and gaining business intelligence through data-mining to defense and strategic systems, weather and climate, physical and life sciences, energy, aerospace and automotive, media and entertainment, semiconductor design and manufacturing, financial services, data centers, and business intelligence and data analytics markets; and enterprise class features for the Linux operating system that provide a standard Linux operating environment. Silicon Graphics International Corp. markets and sells its systems, technologies, software, and services to enterprises in approximately 25 countries through direct and indirect sales force, including distributors, original equipment manufacturers, system integrators, value added resellers, and channel partners. The company was formerly known as Rackable Systems, Inc. and changed its name to Silicon Graphics International Corp. in May 2009. Silicon Graphics International Corp. was incorporated in 2002 and is headquartered in Fremont, Californi a.
Advisors' Opinion:- [By Roberto Pedone]
Silicon Graphics International (SGI) develops, markets and sells various servers, enterprise-class storage hardware, differentiating software and solutions. This stock closed up 3.3% to $9.36 in Thursday's trading session.
Thursday's Range: $9.07-$9.47
52-Week Range: $8.16-$16.60
Thursday's Volume: 179,000
Three-Month Average Volume: 270,564From a technical perspective, SGI bounced notably higher here right above some near-term support at $9 with lighter-than-average volume. This stock has been making higher lows over the last two months, and this stock is now starting to trend within range of triggering a near-term breakout trade. That trade will hit if SGI manages to take out some near-term overhead resistance levels at its 50-day moving average of $9.58 to some more near-term overhead resistance levels at $9.65 to $10.23 with high volume.
Traders should now look for long-biased trades in SGI as long as it's trending above some near-term support levels at $9 or at $8.86 and then once it sustains a move or close above those breakout levels with volume that hits near or above 270,564 shares. If that breakout hits soon, then SGI will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $10.83 to its gap-down-day high of $11 from May. Any high-volume move above $11 will then give SGI a chance to re-fill some of its previous gap-down-day zone that started near $12.50.
- [By John Udovich]
On Thursday, small cap supercomputer stock Cray Inc (NASDAQ: CRAY) announced that it had been rewarded with one of the largest contracts in its history for $174 million to provide the National Nuclear Security Administration (NNSA) with supercomputers - meaning its worth taking a closer look at the stock along with the performance of large caps�like International Business Machines Corp (NYSE: IBM) and�Hewlett-Packard Company (NYSE: HPQ) plus small cap Silicon Graphics International Corp (NASDAQ: SGI) who sort of compete with the company in the supercomputing space. I should�note that over a year ago, we had Cray Inc in�our SmallCap Network Elite Opportunity (SCN EO) trading portfolio�when we had suggested it was�potentially a good�low risk longer-term play.
- [By Alex Planes]
What: Shares of Silicon Graphics (NASDAQ: SGI ) are up by roughly 8% today after having risen as much as 15% by midday. The fluctuations of today's pop seem to be based on swings between a strong earnings report from the company and a bit of underwhelming forward guidance.
- [By Seth Jayson]
Silicon Graphics International (Nasdaq: SGI ) is expected to report Q3 earnings on April 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Silicon Graphics International's revenues will grow 7.7% and EPS will expand 27.3%.
Hot Tech Companies To Buy For 2014: Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.
Taliglucerase Alfa
Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.
PRX-102
The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.
Acetylcholinesterase
Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.
As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.
pr-antiTNF
pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.
The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.
Advisors' Opinion:- [By Keith Speights]
Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."
- [By Maxx Chatsko]
Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.
Hot Tech Companies To Buy For 2014: Avago Technologies Limited(AVGO)
Avago Technologies Limited engages in the design, development, and supply of analog semiconductor devices with a focus on III-V based products. Its product portfolio comprises RF amplifiers, RF filters, RF front-end modules, ambient light sensors, light emitting diodes, low noise amplifiers, mm-wave mixers, optical finger navigation products, diodes, fiber optic transceivers, serializer/deserializer ASICs, motion control encoders and subsystems, optocouplers, and optical mouse sensors. The company?s products are used in cellular phones, consumer appliances, data networking and telecommunications equipment, enterprise storage and servers, renewable energy and smart power grid, factory automation, displays, optical mice, printers, voice and data communications, keypad and display backlighting, backlighting control, base stations, storage area networking, in-car infotainment, lighting, motor controls, power supplies, and optical disk drives applications. It markets its produ cts through a network of distributors and its direct sales force worldwide. The company sells approximately 6,500 products to original equipment manufacturers of wireless communications, wired infrastructure, industrial and automotive electronics, and consumer and computing peripherals markets. Avago Technologies Limited was founded in 2005 and is based in Singapore.
Advisors' Opinion:- [By Evan Niu, CFA]
Analog component supplier Avago Technologies (NASDAQ: AVGO ) is acquiring CyOptics, a maker of optical chip and component technologies for the telecommunications industry, for $400 million in cash, the company announced today.
No comments:
Post a Comment